secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sarepta Therapeutics, Inc. (SRPT)
CIK:        0000873303
Form:       8-K
Filed at:   2025-07-16T23:59:59+00:00
Accession:  0000950170-25-096257
Event type: other_material
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 2.05, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sarepta cuts 36% workforce, reports $513M Q2 revenue, agrees to ELEVIDYS black box warning
--------------------------------------------------------------------------------

- Workforce reduction of ~36% (~500 employees); one-time charge of $32-37M in Q3 2025; annual cost savings of ~$400M.
- Preliminary Q2 2025 net product revenue $513M: ELEVIDYS $282M, PMOs $231M; cash & investments ~$850M.
- FDA requested black box warning for acute liver injury/failure in ELEVIDYS label; Sarepta agrees, resolving material issues for ambulant patients.
- Pipeline reprioritized to focus on siRNA platform; most LGMD gene therapies paused, except SRP-9003 BLA expected H2 2025.
- Executive changes: Ian Estepan as President/COO, Louise Rodino-Klapac as President R&D, Ryan Wong as CFO; Dallan Murray departs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/873303/000095017025096257/0000950170-25-096257-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/873303/000095017025096257/srpt-20250714.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-096257

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer